Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast

Millendo Therapeutics Reports Second Quarter 2019 Operating and Financial Results


Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended June 30, 2019.

"Our ZEPHYR pivotal Phase 2b/3 clinical study in PWS patients is off to a strong start, and we remain on track to report topline results from the Phase 2b portion of the study in the first half of 2020," said Julia C. Owens, President and Chief Executive Officer of Millendo Therapeutics. "In addition, our Phase 2b clinical study of nevanimibe in CAH is enrolling patients under an amended protocol. We expect to provide an update on timelines for the CAH study in the second half of 2019.

"We are announcing today our decision to discontinue the Phase 2 study of nevanimibe in Cushing's syndrome, based on an analysis of the feasibility of patient recruitment and a reprioritization of resources. While this decision was a difficult one, we believe that we are now able to better optimize investments across our portfolio of potential novel therapies in areas of significant unmet need. In line with this commitment, we are excited today to announce the selection of a new compound to begin preclinical development required to support a first-in-human study, MLE-301 for the treatment of vasomotor symptoms associated with menopause. This selective NK3R antagonist enables us to leverage our expertise in VMS drug development."

Second Quarter 2019 and Recent Highlights

"With the strategic reprioritization of our portfolio, we are pleased that our current cash position is expected to support our capital needs into the fourth quarter of 2020," commented Louis J. Arcudi III, Chief Financial Officer.

Second Quarter 2019 Financial Results

Cash Position: Cash, cash equivalents, marketable securities and restricted cash were $56.6 million at June 30, 2019, compared to $78.2 million at December 31, 2018.

Research and Development (R&D) Expenses: R&D expenses were $6.0 million for the second quarter 2019, as compared to $3.2 million for the same period in 2018. The increase in R&D expenses was primarily driven by increased spending on the company's pivotal Phase 2b/3 study of livoletide in PWS and higher compensation expenses as a result of increased headcount.

General and Administrative (G&A) Expenses: G&A expenses were $4.2 million for the second quarter 2019, as compared to $1.8 million for the same period in 2018. The increase in G&A expenses was primarily driven by higher compensation expense as a result of increased headcount and increased professional and other fees to support ongoing business operations and obligations associated with being a publicly traded company.

Net Loss: The company's net loss for the quarter ended June 30, 2019 was $9.9 million as compared to $5.0 million for the same period in 2018.

2019 Financial Guidance

Millendo expects that its cash, cash equivalents, marketable securities and restricted cash will support the company's capital needs into the fourth quarter of 2020, beyond the readout for the topline results of the Phase 2b portion of the pivotal Phase 2b/3 study of livoletide in PWS, which is expected in the first half of 2020. This cash runway guidance is based on the company's current operational plans and excludes any additional funding or business development activities.

About Livoletide
Millendo's lead asset, livoletide, is an unacylated ghrelin analogue in late-stage clinical development for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characterized by hyperphagia, a chronic unrelenting hunger, that leads to obesity, metabolic dysfunction, reduced quality of life and early mortality. In March 2019, the company initiated a pivotal Phase 2b/3 clinical study of livoletide in patients with PWS. In a previous randomized, double-blind, placebo-controlled Phase 2 clinical trial in 47 patients with PWS, administration of livoletide once daily was associated with a clinically meaningful improvement in hyperphagia, as well as a reduction in appetite. For more information about Millendo's pivotal study of livoletide (ZEPHYR) please visit www.clinicaltrials.gov (NCT03790865) or the Patients and Families portion of our website.

About Nevanimibe
Nevanimibe decreases adrenal steroidogenesis through the inhibition of ACAT1 and is being studied for the treatment of classic congenital adrenal hyperplasia (CAH). CAH is a rare, monogenic adrenal disease that requires lifelong treatment with exogenous cortisol, often at high doses, which can make it difficult for physicians to appropriately treat CAH without causing adverse consequences. In a Phase 2 proof-of-concept clinical trial in patients with CAH, Millendo observed nevanimibe to be associated with clear signs of clinical activity in seven of 10 treated patients. A Phase 2b trial of nevanimibe in CAH (NCT03669549) is ongoing.

About MLE-301
MLE-301 is an investigational, neurokinin 3 receptor (NK3R) antagonist that acts to normalize the activity of KNDy (kisspeptin/NKB/dynorphin) neurons, which are overactive in menopausal women and play an important role in the generation of vasomotor symptoms (VMS). MLE-301 works by reducing neurokinin B signaling via KNDy neurons and is hypothesized to reduce the frequency and severity of VMS. Millendo is advancing MLE-301 for the treatment of VMS associated with menopause through preclinical development to enable first-in-human clinical studies.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding Millendo's expectations regarding the potential for an NDA submission for livoletide, the timing of data from its clinical trials, including the timing of topline data from the Phase 2b portion of its ZEPHYR trial, and the timeline for its Phase 2b clinical study of nevanimibe in CAH, the potential and timing for MLE-301 to enter clinical trials, the potential of a future product launch, the potential advantages of Millendo's discontinuation of its Phase 2 study of nevanimibe in CS, the potential impact of Fast Track designation, Millendo's expectations regarding its 2019 and 2020 milestones, and Millendo's expectations regarding its cash runway, and, therefore, you are cautioned not to place undue reliance on them. In some cases, you can identify forward-looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Such forward-looking statements are based on Millendo's expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including that Millendo has incurred significant losses since inception, Millendo has a limited operating history and has never generated any revenue from product sales, Millendo will require additional capital to finance its operations, Millendo's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of livoletide, nevanimibe and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Millendo's clinical trials may not support Millendo's livoletide or nevanimibe claims, Millendo may encounter substantial delays in its clinical trials or Millendo may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Millendo's control, Millendo's product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential and Millendo faces substantial competition. You should refer to the risk factor disclosure set forth in the periodic reports and other documents we file with the SEC available at www.sec.gov, including without limitation our Annual Report on Form 10-K for our fiscal year ended December 31, 2018 and our Quarterly Report on Form 10-Q for our fiscal quarter ended June 30, 2019.

New factors emerge from time to time and it is not possible for Millendo to predict all such factors, nor can Millendo assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to Millendo as of the date of this press release. Millendo disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

 

Millendo Therapeutics, Inc.

Condensed Statements of Operations
(in thousands except share and per share amounts)
 

Three Months Ended

 

Six Months Ended

 

 

 

June 30,

 

June 30,

 

 

 

 

2019

 

 

 

2018

 

 

 

2019

 

 

 

2018

 

Operating Expenses
Research and development

$

5,981

 

$

3,200

 

$

12,185

 

$

5,969

 

General and administrative

 

4,179

 

 

1,786

 

 

8,632

 

 

3,405

 

Loss from operations

 

10,160

 

 

4,986

 

 

20,817

 

 

9,374

 

 
Other (income) expense, net

 

(289

)

 

56

 

 

(580

)

 

54

 

Net loss

 

(9,871

)

 

(5,042

)

 

(20,237

)

 

(9,428

)

Net loss attributable to noncontrolling interest

 

-

 

 

196

 

 

-

 

 

321

 

Net loss attributable to common stockholders

$

(9,871

)

$

(4,846

)

$

(20,237

)

$

(9,107

)

Net loss per share of common stock, basic and diluted

$

(0.74

)

$

(6.82

)

$

(1.51

)

$

(12.82

)

Weighted-average shares of common stock outstanding, basic and diluted

 

13,379,842

 

 

710,390

 

 

13,368,981

 

 

710,390

 

 
 
Millendo Therapeutics, Inc.
Condensed Balance Sheet Data
(in thousands)
 

June 30,

 

December 31,

 

 

 

 

 

 

 

 

2019

 

 

 

2018

 

 

Cash, cash equivalents, marketable securities and restricted cash

$

56,631

 

$

78,155

 

Other assets

 

11,693

 

 

5,919

 

Total assets

$

68,324

 

$

84,074

 

 
Total liabilities

$

13,299

 

$

10,952

 

Total stockholders' equity

 

55,025

 

 

73,122

 

Total liabilities and stockholders' equity

$

68,324

 

$

84,074

 

 

 


These press releases may also interest you

at 11:40
T-Systems has signed a multi-year partnership agreement with Corent Technology - a technology leader in Cloud Migration, Modernization, Optimization and SaaS transformation automation technologies. This follows an extensive vendor selection process...

at 11:35
Today, Meter, a leading provider of internet infrastructure solutions for businesses, announced the launch of the Meter Partner Program. With Meter's Network as a Service (NaaS) solution now powering tens of millions of square feet in over 125...

at 11:34
The narrow front and rear lights, which were developed by ZKW in Wieselburg, are very unusual. At the front, the dark, high-resolution LED headlamps blend harmoniously into the front of the BMW XM. At the rear of the powerful SUV, BMW relies on...

at 11:32
AI21, the leader in AI systems for the enterprise, today unveiled Jamba, the world's first production-grade Mamba-style model ? integrating Mamba Structured State Space model (SSM) technology with elements of traditional Transformer architecture....

at 11:30
SharpQuest, Inc., a software services provider with a niche in cloud and mobile-app solutions, is thrilled to announce the opening of its new branch office in Windsor, Ontario, Canada. This strategic expansion marks a significant milestone in our...

at 11:30
Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services. Trianz has embarked on a transformative journey, redefining its value proposition...



News published on and distributed by: